On May 1, 2025, Armata Pharmaceuticals, Inc. announced it received $4.65 million in non-dilutive funding from the U.S. Department of Defense to develop bacteriophage therapy for Staphylococcus aureus infections.
AI Assistant
ARMATA PHARMACEUTICALS INC
2025
8 K
Find Answers
Ask about any part of the document to get insights, explanations, or key details.